Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer
BRISBANE, Australia, Oct. 8, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its first-in-human Phase I clinical trial of CYT-101.
CYT-101 is a novel off-the-shelf, HLA-matched CMV-specific T cell therapy...




